Thrombolytic TherapyStreptokinaseMyeloid Differentiation Factor 88Fibrinolytic AgentsPlasminogen ActivatorsMyocardial InfarctionAnistreplaseHeparinRecombinant ProteinsTreatment OutcomeImmunoglobulin Fab FragmentsUrokinase-Type Plasminogen ActivatorStrokePulmonary EmbolismBrain IschemiaHemorrhageCerebral HemorrhageMyocardial ReperfusionMycosis FungoidesEmbolectomyThrombosisAcute DiseaseCoronary AngiographyCoronary Care UnitsAnticoagulantsFibrinolysisDrug Therapy, CombinationHeart Rupture, Post-InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexIntracranial ThrombosisTherapeutic EquivalencyElectrocardiographyIntracranial HemorrhagesPlatelet Aggregation InhibitorsAngioplasty, Balloon, CoronaryFibrinolysinCarotid Artery ThrombosisInfusions, IntravenousProspective StudiesCoronary ThrombosisEmergency Medical ServicesRecurrenceIntracranial Embolism and ThrombosisInjections, IntravenousVascular PatencyEmergenciesInfusions, Intra-ArterialTomography, X-Ray ComputedPlatelet AggregationIntracranial EmbolismVenous ThrombosisCerebral InfarctionHirudin TherapyEmergency TreatmentCreatine KinaseEmergency Medical TechniciansRadionuclide VentriculographyRetrospective StudiesHospital MortalityInjections, Intra-ArterialThrombectomyReperfusionFibrinopeptide ACerebral AngiographyFollow-Up StudiesFibrinogenFibrinEye HemorrhageAntibodies, MonoclonalPatient SelectionNewfoundland and LabradorHeart RuptureRandomized Controlled Trials as TopicCatheterization, PeripheralStreptodornase and StreptokinaseMolluscacidesAspirinCarboxylic AcidsEcchymosisPredictive Value of TestsInfarction, Middle Cerebral ArteryRisk FactorsCerebrovascular DisordersBlood CoagulationPrognosisArterial Occlusive DiseasesFibrin Fibrinogen Degradation ProductsHospitals, CommunityCardiac CatheterizationShock, CardiogenicVentricular Septal RupturePlasminogenInfarction, Anterior Cerebral ArteryRegistriesSurvival RateMultivariate AnalysisIliac VeinHemostasisStatistics, NonparametricEurope